A study published in Cancer Cell suggests that cancer patients who were vaccinated against COVID-19 attained high seroconversion rates.

The rate of seroconversion was found to be particularly high among patients who had solid tumors (98%). Patients with hematological malignancies had lower rates of seroconversion (85%), especially those who had undergone highly immunosuppressive therapies. Patients with hematological malignancies were also reported to have significantly lower titer levels in comparison with patients with solid tumor and non-cancer controls, reported researchers. Balazs Halmos of Montefiore Medical Center in New York City stated that the study suggests COVID-19 vaccines are safe and effective for most patients with cancer… (Medpage Today)